Beijing Sun-Novo Secures Clinical Trial Approval for Heart Failure Treatment Candidate BTP0427

Stock News

4 hours ago

Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. (688621.SH) has announced that it, together with its wholly-owned subsidiary Jiangsu Novobita New Drug Research and Development Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration. The approval covers the company's investigational project BTP0427, clearing the way for its clinical trial application.

BTP0427 is intended for use in treating chronic heart failure with reduced ejection fraction. It is designed for symptomatic treatment in patients with chronic heart failure due to cardiac systolic dysfunction, serving as an alternative therapy for individuals whose condition is well-controlled and who are already receiving a combination of beta-blockers and sinoatrial node If current inhibitors at the same dosage.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1106853030"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106853030\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106853030?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-16 17:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106853030","market":"sg","top_or_hot":-1,"title":"Beijing Sun-Novo Secures Clinical Trial Approval for Heart Failure Treatment Candidate BTP0427","media":"Stock News","content":"<p><b>Beijing Sun-Novo Pharmaceutical Research Co.,Ltd.</b> (<b>688621.SH</b>) has announced that it, together with its wholly-owned subsidiary Jiangsu Novobita New Drug Research and Development Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration. The approval covers the company's investigational project BTP0427, clearing the way for its clinical trial application.<br><br>BTP0427 is intended for use in treating chronic heart failure with reduced ejection fraction. It is designed for symptomatic treatment in patients with chronic heart failure due to cardiac systolic dysfunction, serving as an alternative therapy for individuals whose condition is well-controlled and who are already receiving a combination of beta-blockers and sinoatrial node If current inhibitors at the same dosage.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Sun-Novo Secures Clinical Trial Approval for Heart Failure Treatment Candidate BTP0427</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Sun-Novo Secures Clinical Trial Approval for Heart Failure Treatment Candidate BTP0427\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-16 17:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Beijing Sun-Novo Pharmaceutical Research Co.,Ltd.</b> (<b>688621.SH</b>) has announced that it, together with its wholly-owned subsidiary Jiangsu Novobita New Drug Research and Development Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration. The approval covers the company's investigational project BTP0427, clearing the way for its clinical trial application.<br><br>BTP0427 is intended for use in treating chronic heart failure with reduced ejection fraction. It is designed for symptomatic treatment in patients with chronic heart failure due to cardiac systolic dysfunction, serving as an alternative therapy for individuals whose condition is well-controlled and who are already receiving a combination of beta-blockers and sinoatrial node If current inhibitors at the same dosage.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"","article_id":"1106853030","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106853030","pubTimestamp":1789551493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. (688621.SH) has announced that it, together with its wholly-owned subsidiary Jiangsu Novobita New Drug Research and Development Co., Ltd., has...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688621":"阳光诺和","BK0216":"研究试验","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","MDTX":"Corgi MediaTek 2x Daily ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","BMED":"iShares Health Innovation Active ETF","PSYK":"PSYK ETF"},"translate_title":"北京新和获得心力衰竭治疗候选药物BTP0427临床试验批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688621":1,"IBBQ":1,"MDTX":1,"PSYK":1,"BMED":1,"IBBJ":1},"content_text":"Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. (688621.SH) has announced that it, together with its wholly-owned subsidiary Jiangsu Novobita New Drug Research and Development Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration. The approval covers the company's investigational project BTP0427, clearing the way for its clinical trial application.BTP0427 is intended for use in treating chronic heart failure with reduced ejection fraction. It is designed for symptomatic treatment in patients with chronic heart failure due to cardiac systolic dysfunction, serving as an alternative therapy for individuals whose condition is well-controlled and who are already receiving a combination of beta-blockers and sinoatrial node If current inhibitors at the same dosage.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}